Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: A comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcomes

Journal of Clinical Epidemiology

Volumn 66, Issue 8 SUPPL.8, 2013, Pages

  Dore, David D ^a   Swaminathan, Shailender ^a   Gutman, Roee ^a   Trivedi, Amal N ^a,b   Mor, Vincent ^a,b  

^a BROWN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Causal inference; Comparative effectiveness research; Dialysis; End stage renal disease; Methods; Pharmacoepidemiology

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; ERYTHROPOIETIN STIMULATING AGENT; UNCLASSIFIED DRUG;

ARTICLE; HEALTH CARE POLICY; HEMATOCRIT; HUMAN; INCIDENCE; INSTRUMENTAL VARIABLE ANALYSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MEDICAID; MEDICAL FEE; MEDICARE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SURVIVAL;

CAUSAL INFERENCE; COMPARATIVE EFFECTIVENESS RESEARCH; DIALYSIS; END-STAGE RENAL DISEASE; METHODS; PHARMACOEPIDEMIOLOGY;

AGED; ANEMIA; CAUSALITY; COMPARATIVE EFFECTIVENESS RESEARCH; DATA INTERPRETATION, STATISTICAL; FEMALE; HEMATINICS; HEMATOCRIT; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; POLICY; PROPENSITY SCORE; QUALITY INDICATORS, HEALTH CARE; REIMBURSEMENT MECHANISMS; RENAL DIALYSIS; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES;

EID: 84880199996     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2013.02.014     Document Type: Article

References (40)

1. P.W. Holland Statistics and causal inference J Am Stat Assoc 81 1986 945 960
2. B.E. Dowd Separated at birth: statisticians, social scientists, and causality in health services research Health Serv Res 46 2011 397 420
3. J. Pearl Statistics and causality: separated to reunite-commentary on Bryan Dowd's "Separated at birth" Health Serv Res 46 2011 421 429
4. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective JAMA 307 2012 1636 1640
5. S. Schneeweiss Developments in post-marketing comparative effectiveness research Clin Pharmacol Ther 82 2007 143 156 (Pubitemid 47075343)
6. R.H. Dehejia, and S. Wahba Causal effects in, nonexperimental studies: reevaluating the evaluation of training programs J Am Stat Assoc 94 1999 1053 1062
7. J.D. Angrist, G.W. Imbens, and D.B. Rubin Identification of causal effects using instrumental variables J Am Stat Assoc 91 1996 444 455 (Pubitemid 126412813)
8. O. Galarraga, D.S. Salkever, J.A. Cook, and S.J. Gange An instrumental variables evaluation of the effect of antidepressant use on employment among HIV-infected women using antiretroviral therapy in the United States: 1996-2004 Health Econ 19 2010 173 188
9. Aranesp (darbepoetin alfa) Package Insert 2002 Amgen Thousand Oaks, CA
10. R. Gutman, and D.B. Rubin Analyses that inform policy decisions Biometrics 68 2012 671 675 10.1111/j.1541-0420.2011.01732.x
11. A.R. Nissenson, T.J. Mayne, and M. Krishnan The 2011 ESRD prospective payment system: perspectives from DaVita, a for-profit large dialysis organization Am J Kidney Dis 57 2011 550 552
12. A. Besarab, W.K. Bolton, J.K. Browne, J.C. Egrie, A.R. Nissenson, and D.M. Okamoto The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin N Engl J Med 339 1998 584 590 (Pubitemid 28385655)
13. T.B. Drueke, F. Locatelli, N. Clyne, K.U. Eckardt, I.C. Macdougall, and D. Tsakiris Normalization of hemoglobin level in patients with chronic kidney disease and anemia N Engl J Med 355 2006 2071 2084 (Pubitemid 44749316)
14. M.A. Pfeffer, E.A. Burdmann, C.Y. Chen, M.E. Cooper, D. de Zeeuw, and K.U. Eckardt A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease N Engl J Med 361 2009 2019 2032
15. A.K. Singh, L. Szczech, K.L. Tang, H. Barnhart, S. Sapp, and M. Wolfson Correction of anemia with epoetin alfa in chronic kidney disease N Engl J Med 355 2006 2085 2098 (Pubitemid 44749317)
16. US Food and Drug Administration: Postmarketing drug safety information for patients and providers. Approved Risk Evaluation and Mitigation Strategies (REMS). Available at http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ucm109375.htm. Accessed December 13, 2010.
17. Erythropoiesis-stimulating agents (ESAs) in chronic kidney disease: drug safety communication - modified dosing recommendations. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm260641.htm. Accessed June 24, 2011.
18. R.J.A. Little, and D.B. Rubin Statistical analysis with missing data 1987 J. Wiley & Sons New York, NY
19. S. Suissa Immortal time bias in observational studies of drug effects Pharmacoepidemiol Drug Saf 16 2007 241 249 (Pubitemid 46431687)
20. S. Suissa Immortal time bias in pharmaco-epidemiology Am J Epidemiol 167 2008 492 499
21. M.A. Hernan, S. Hernandez-Diaz, and J.M. Robins A structural approach to selection bias Epidemiology 15 2004 615 625 (Pubitemid 40416916)
22. P.R. Rosenbaum, and D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
23. G.W. Imbens, and D.B. Rubin Causal inference in statistics, and in the social and biomedical sciences 2012 Cambridge University Press Cambridge
24. T. Stürmer, K.J. Rothman, J. Avorn, and R.J. Glynn Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution-a simulation study Am J Epidemiol 172 2010 843 854
25. D.B. Rubin Multiple imputation for nonresponse in surveys 1987 John Wiley & Sons Inc New York, NY
26. R. Gutman, and D.B. Rubin Robust estimation of causal effects of binary treatments in unconfounded studies with dichotomous outcomes Stat Med 32 2013 1795 1814
27. CMS: 42 CFR Parts 410, 413 and 414 Fed Regist 75 2010 49037
28. D. Staiger, and J.H. Stock Instrumental variables regression with weak instruments Econometrica 65 1997 557 586 (Pubitemid 127466159)
29. D.B. Rubin Bayesian-inference for causal effects - role of randomization Ann Stat 6 1978 34 58
30. M.A. Hernan, and J.M. Robins Instruments for causal inference: an epidemiologist's dream? Epidemiology 17 2006 360 372 (Pubitemid 44305508)
31. G.W. Imbens, and J.D. Angrist Identification and estimation of local average treatment effects Econometrica 62 1994 467 475
32. A. Basu, J.J. Heckman, S. Navarro-Lozano, and S. Urzua Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients Health Econ 16 2007 1133 1157 (Pubitemid 350065184)
33. M.A. Brookhart, S. Schneeweiss, J. Avorn, B.D. Bradbury, J. Liu, and W.C. Winkelmayer Comparative mortality risk of anemia management practices in incident hemodialysis patients JAMA 303 2010 857 864
34. J. Bound, D.A. Jaeger, and R.M. Baker Problems with instrumental variables estimation when the correlation between the instruments and the endogenous explanatory variable is weak J Am Stat Assoc 90 1995 443 450
35. D.B. Rubin On the limitations of comparative effectiveness research Stat Med 29 2010 1991 1995 discussion 1996-7
36. T. Kurth, A.M. Walker, R.J. Glynn, K.A. Chan, J.M. Gaziano, and K. Berger Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect Am J Epidemiol 163 2006 262 270 (Pubitemid 43145754)
37. Y. Zhang, M. Thamer, D. Cotter, J. Kaufman, and M.A. Hernan Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States Clin J Am Soc Nephrol 4 2009 638 644
38. P.A. Gabow Autosomal dominant polycystic kidney disease N Engl J Med 329 1993 332 342 (Pubitemid 23210687)
39. W.A. Ray Evaluating medication effects outside of clinical trials: new-user designs Am J Epidemiol 158 2003 915 920 (Pubitemid 37323253)
40. J.M. Robins, M.A. Hernan, and B. Brumback Marginal structural models and causal inference in epidemiology Epidemiology 11 2000 550 560 (Pubitemid 30660034)